SCHEMBL7675792

SCHEMBL7675792

N#Cc1ccc(Cc2ccnc(Cl)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 6/20 0.44
HRH3 Q9Y5N1 1/20 0.43
LOXL2 Q9Y4K0 2/20 0.41
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
CYP2A6 P11509 1/20 0.39
FFAR1 O14842 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
SAE1 Q9UBE0 1/20 0.37
UBA2 Q9UBT2 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7675938 0.82 HRH3 (0.48) CYP19A1HRH3CYP11B1CYP11B2ALDH1A1
SCHEMBL7674816 0.78 HTR2C (0.38) CYP19A1CYP11B1CYP11B2KDM4ETLR8
SCHEMBL265376 0.78 ALDH1A1 (0.47) CYP19A1ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL7542738 0.75 ALDH1A1 (0.39) CYP11B1CYP11B2ALDH1A1CYP1A2HPGD
SCHEMBL7672911 0.74 MBOAT4 (0.44) TLR8TLR7
SCHEMBL17537258 0.73 NR4A2 (0.42) LOXL2FFAR1ALDH1A1HPGD
SCHEMBL17664102 0.72 MAOA (0.45) CYP19A1HRH3LOXL2CYP11B1CYP11B2
SCHEMBL3174027 0.72 CYP19A1 (0.40) CYP19A1KDM4EALDH1A1HPGDTLR8
SCHEMBL5140285 0.72 MEN1 (0.42) FFAR1KDM4E
SCHEMBL4378433 0.71 MEN1 (0.48) CYP19A1CYP11B2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020035092-A1 Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid CELLTECH THERAPEUTICS LIMITED 2002-03-21 US disclosed
US-6319922-B1 ALPHA-PYRIMIDYL-SUBSTITUTED; USEFUL FOR TREATING DISEASES INCLUDING INFLAMMATORY DISEASES, AND DISEASES INVOLVING ANGIOGENESIS, BONE RESORPTION OR CELLULAR OR MATRIX OVER-EXPANSION. CELLTECH THERAPEUTICS LIMITED (GB) 2001-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035092-A1 Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid ITGA1, ITGB1, VCAM1 CYP19A1 3348/4885HRH3 150/4885LOXL2 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.